Insights

Why the Respiri (ASX:RSH) share price opened higher today

The Respiri Ltd (ASX:RSH) share price opened higher today after the company announced plans to launch its Wheezo app in the United Kingdom.
The post Why the Respiri (ASX:RSH) share price opened higher today appeared first on The Motley Fool Australia. –

medical asx share price represented by doctor giving thumbs up

Respiri Ltd (ASX: RSH) shares were on the move this morning after the company announced it will be launching its Wheezo brand in the United Kingdom. The Respiri share price opened around 3% higher following the news. However, at the time of writing, the company’s shares have retreated back to 16 cents, flat for the day so far.

The software-as-a-service (Saas) company also advised today that two new executives will be joining its board as strategic advisors.

Let’s look further into the company’s announcements.

Wheezo UK launch

The Respiri share price was temporarily boosted today after the company stated it plans to launch Wheezo in the UK. The combination app and device product aims to help those with asthma manage the condition. The company said it is on track to launch in the UK market in late 2021.

This comes after Respiri’s news on Tuesday that Wheezo has received United States Food and Drug Administration (FDA) clearance.

Respiri is in discussions with multinational pharmaceutical company Cipla and other potential partners ahead of Wheezo’s UK launch.

Further, Respiri states it’s in discussions with leading clinicians in the UK regarding the company’s participation as a technology partner in multiple, large, asthma-related studies. These studies are expected to provide evidence for the use of asthma therapeutics and the role of digital technologies in the management of paediatric asthma.

The company says better asthma management has the potential to lead to improved outcomes and quality of life for those with the condition.

Advisor appointments to Respiri board

In further news impacting the Respiri share price this morning, the company also announced it has recently appointed two new advisors to its board.

Dr Andrew Weekes and Dr Mark Levy will aid the company in its UK launch, according to the announcement.

Dr Weekes is the country medical director for Australia of GlaxoSmithKline (NYSE: GSK). Respiri states GlaxoSmithKline is a leading global player in respiratory diseases. Dr Weekes will provide advice to Respiri’s board regarding Wheezo’s commercialisation, its clinical development and other subjects.    

Dr Levy has been appointed as an advisor for the UK. He has been a member of the Global Initiative for Asthma executive board since 2009. Respiri CEO Marjan Mikel said Dr Levy has provided the board with advice and introductions ahead of its UK launch.

Respiri share price snapshot

The Respiri share price is having a stellar year on the ASX and is currently up by 23.08% year to date. It is also up by nearly 83% over the last 12 months.

The company has a market capitalisation of around $115 million, with approximately 722 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Respiri (ASX:RSH) share price opened higher today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!